• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性阻塞性肺疾病的三联疗法：解读相关数据。

Triple therapy in COPD: understanding the data.

作者信息

Suissa Samy

机构信息

Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, QC, Canada.

Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada.

出版信息

ERJ Open Res. 2023 Jan 30;9(1). doi: 10.1183/23120541.00615-2022. eCollection 2023 Jan.

DOI:10.1183/23120541.00615-2022
PMID:36726367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9885273/
Abstract

https://bit.ly/3tOgNdW.

摘要

https://bit.ly/3tOgNdW. （此为网址，无法准确翻译其内容，保留原样）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e01/9885273/09a94d986186/00615-2022.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e01/9885273/74c8eef7a83c/00615-2022.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e01/9885273/09a94d986186/00615-2022.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e01/9885273/74c8eef7a83c/00615-2022.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e01/9885273/09a94d986186/00615-2022.02.jpg

相似文献

1
Triple therapy in COPD: understanding the data.慢性阻塞性肺疾病的三联疗法：解读相关数据。
ERJ Open Res. 2023 Jan 30;9(1). doi: 10.1183/23120541.00615-2022. eCollection 2023 Jan.
2
Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials.三联单吸入器治疗与双联单吸入器治疗慢性阻塞性肺疾病患者的疗效比较：一项随机对照试验的荟萃分析。
Respir Res. 2021 Jul 23;22(1):209. doi: 10.1186/s12931-021-01794-w.
3
Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety.COPD 单吸入器三联与双联支气管扩张剂治疗：真实世界的比较疗效和安全性。
Int J Chron Obstruct Pulmon Dis. 2022 Aug 30;17:1975-1986. doi: 10.2147/COPD.S378486. eCollection 2022.
4
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.一项使用共悬浮递送技术的布地奈德/格隆溴铵/富马酸福莫特罗三药联合治疗中重度至极重度 COPD 的 III 期研究：ETHOS 研究方案。
Respir Med. 2019 Oct-Nov;158:59-66. doi: 10.1016/j.rmed.2019.08.010. Epub 2019 Aug 22.
5
The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.52周单吸入器装置三联疗法与双联疗法对慢性阻塞性肺疾病患者死亡率的影响：一项随机对照试验的系统评价和荟萃分析
Life (Basel). 2022 Jan 25;12(2):173. doi: 10.3390/life12020173.
6
Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality.三联吸入器与双支气管扩张剂疗法治疗慢性阻塞性肺疾病：对死亡率的真实世界疗效
COPD. 2022 Dec;19(1):1-9. doi: 10.1080/15412555.2021.1977789. Epub 2021 Sep 21.
7
Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice.COPD 三联疗法中停用吸入性皮质类固醇：对真实世界临床实践中主要结局的影响。
COPD. 2022;19(1):133-141. doi: 10.1080/15412555.2022.2045265.
8
The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.单吸入器三联疗法与单吸入器双联疗法或单独三联疗法治疗慢性阻塞性肺疾病的效果：系统评价和随机对照试验的荟萃分析。
Int J Chron Obstruct Pulmon Dis. 2019 Jul 11;14:1539-1548. doi: 10.2147/COPD.S200846. eCollection 2019.
9
Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain.西班牙慢性阻塞性肺疾病患者布地奈德/格隆溴铵/富马酸福莫特罗三联疗法与双联疗法的成本-效果分析。
Int J Chron Obstruct Pulmon Dis. 2022 Nov 15;17:2905-2917. doi: 10.2147/COPD.S384591. eCollection 2022.
10
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.布地奈德/格隆溴铵/富马酸福莫特罗二水化合物三联疗法与中重度至极重度慢性阻塞性肺疾病的双重疗法相比的成本效益：ETHOS 研究的英国分析。
Int J Chron Obstruct Pulmon Dis. 2022 Nov 22;17:2987-3000. doi: 10.2147/COPD.S381138. eCollection 2022.

引用本文的文献

1
Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease.呼吸系统疾病中的患者反应与缓解：特别关注重度哮喘和慢性阻塞性肺疾病
J Int Med Res. 2025 May;53(5):3000605251340894. doi: 10.1177/03000605251340894. Epub 2025 May 20.
2
Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions.治疗慢性阻塞性肺疾病的分子方法：当前观点与未来方向
Int J Mol Sci. 2025 Feb 28;26(5):2184. doi: 10.3390/ijms26052184.
3
Emulating randomized trials by observational database studies: the RCT-DUPLICATE initiative in COPD and asthma.

本文引用的文献

1
Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety.COPD 单吸入器三联与双联支气管扩张剂治疗：真实世界的比较疗效和安全性。
Int J Chron Obstruct Pulmon Dis. 2022 Aug 30;17:1975-1986. doi: 10.2147/COPD.S378486. eCollection 2022.
2
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.在慢性阻塞性肺疾病患者中，先前使用吸入性皮质类固醇与布地奈德/格隆溴铵/富马酸福莫特罗二水化合物对加重、症状、健康相关生活质量和肺功能的获益之间的关系：来自 ETHOS 研究的分析。
Respir Med. 2022 Jun;197:106857. doi: 10.1016/j.rmed.2022.106857. Epub 2022 Apr 22.
3
通过观察性数据库研究模拟随机试验：慢性阻塞性肺疾病和哮喘领域的RCT - DUPLICATE计划
Am J Epidemiol. 2025 May 7;194(5):1152-1159. doi: 10.1093/aje/kwae319.
4
The Current Molecular and Cellular Landscape of Chronic Obstructive Pulmonary Disease (COPD): A Review of Therapies and Efforts towards Personalized Treatment.慢性阻塞性肺疾病（COPD）的当前分子和细胞格局：治疗方法及个性化治疗进展综述
Proteomes. 2024 Aug 16;12(3):23. doi: 10.3390/proteomes12030023.
5
Optimizing Pharmacotherapy Management of Chronic Obstructive Pulmonary Disease: Don't Miss the Forest for the Trees.优化慢性阻塞性肺疾病的药物治疗管理：勿只见树木不见森林。
Am J Respir Crit Care Med. 2024 Sep 1;210(5):545-547. doi: 10.1164/rccm.202402-0338VP.
6
Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History.吸入性皮质类固醇在慢性阻塞性肺疾病患者中的应用：一段古老而未完的历史。
Biomolecules. 2024 Feb 6;14(2):195. doi: 10.3390/biom14020195.
7
Comorbidities in COPD: Current and Future Treatment Challenges.慢性阻塞性肺疾病的合并症：当前及未来的治疗挑战
J Clin Med. 2024 Jan 27;13(3):743. doi: 10.3390/jcm13030743.
Triple Therapy in COPD: Time for Adaptive Selection Trials.慢性阻塞性肺疾病的三联疗法：开展适应性选择试验的时候了。
COPD. 2021 Dec;18(6):597-601. doi: 10.1080/15412555.2021.1982886. Epub 2021 Sep 27.
4
Perplexing mortality data from triple therapy trials in COPD.慢性阻塞性肺疾病三联疗法试验中令人困惑的死亡率数据。
Lancet Respir Med. 2021 Jul;9(7):684-685. doi: 10.1016/S2213-2600(21)00238-1. Epub 2021 Jun 11.
5
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.ETHOS 研究中布地奈德/格隆溴铵/福莫特罗治疗慢性阻塞性肺疾病降低全因死亡率：一项随机、双盲、多中心、平行分组研究。
Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC.
6
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.IMPACT 研究中吸入性皮质类固醇停药和基线吸入治疗对加重的影响。一项随机、双盲、多中心临床试验。
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1237-1243. doi: 10.1164/rccm.201912-2478OC.
7
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.中重度至极重度 COPD 患者两种糖皮质激素剂量三联吸入治疗。
N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24.
8
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.氟替卡松维兰特罗/乌美溴铵粉雾剂降低慢性阻塞性肺疾病患者全因死亡率。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC.
9
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.全球慢性阻塞性肺疾病诊断、管理和预防策略：GOLD 科学委员会报告 2019.
Eur Respir J. 2019 May 18;53(5). doi: 10.1183/13993003.00164-2019. Print 2019 May.
10
Triple therapy trials in COPD: a precision medicine opportunity.慢性阻塞性肺疾病的三联疗法试验：精准医学的契机。
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01848-2018. Print 2018 Dec.